Practical Approach to Initiation of Recombinant Human Erythropoietin Therapy and Prevention and Management of Adverse Effects

1990 ◽  
Vol 10 (2) ◽  
pp. 7-14 ◽  
Author(s):  
P.A. Abraham ◽  
P.A. Abraham
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Practical Approach ◽  
Human Erythropoietin

Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients

2017 ◽  
Vol 68 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Andrei Niculae ◽  
Cristiana David ◽  
Razvan Florin Ion Dragomirescu ◽  
Ileana Peride ◽  
Flavia Liliana Turcu ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Best Practice ◽  
Daily Practice ◽  
Therapeutic Benefit ◽  
Chronic Dialysis ◽  
Dialysis Patients ◽  
Protein Levels ◽  
Human Erythropoietin ◽  
Inflammatory Status

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.

scholarly journals Potency Evaluation of Recombinant Human Erythropoietin in Brazil: Assessment of Reproducibility Using a Practical Approach

2015 ◽  
Vol 58 (4) ◽  
pp. 562-568
Author(s):  
Michele Cardoso do Nascimento ◽  
Clarice Lima do Canto Abreu ◽  
Rodrigo Netto Costa ◽  
Wlamir Correa de Moura Delgado ◽  
Isabella Fernandes
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Practical Approach ◽  
Human Erythropoietin

E

2020 ◽  
pp. 275-307
Author(s):  
Sean Ainsworth
Keyword(s):  
Adverse Effects ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Recombinant Human Erythropoietin ◽  
Eye Drops ◽  
Enzyme Replacement ◽  
Maternal Treatment ◽  
Human Erythropoietin

This chapter presents information on neonatal drugs that begin with E, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Enemas, laxatives, and suppositories, Enoxaparin, Enzyme replacement therapy, Epoetin (recombinant human erythropoietin = rEPO), Epoprostenol and other prostanoids (iloprost and teoprostinil), Erythromycin, Esomeprazole, Ethambutol, and Eye drops (and ointments)

Biochemical and Biological Quality Control of Two Recombinant Human Erythropoietin Biosimilar Products

2017 ◽  
Vol 13 (6) ◽  
Author(s):  
Rym Hassiki ◽  
Jamila Behi ◽  
Nadia Ben Said ◽  
Lassaad Boujbel ◽  
Balkiss Bouhaouala-Zahar
Keyword(s):  
Quality Control ◽  
Recombinant Human Erythropoietin ◽  
Biological Quality ◽  
Human Erythropoietin

scholarly journals Effect of Recombinant Human Erythropoietin on Nutritional Status and Plasma Lipids in Uremic Patients

Nephron ◽  
1992 ◽  
Vol 60 (2) ◽  
pp. 249-249 ◽  
Author(s):  
B. Viron ◽  
R. Donsimoni ◽  
C. Michel ◽  
R. Al Khayat ◽  
F. Mignon
Keyword(s):  
Nutritional Status ◽  
Recombinant Human Erythropoietin ◽  
Plasma Lipids ◽  
Human Erythropoietin ◽  
Uremic Patients
Sign in / Sign up

Export Citation Format

Share Document